The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The rerate feels totally managed and if SAR has a strategy to deliver more value, then more RNS will follow. We might not get the end of the POC but I honestly feel there is more to come before the end of June.
Ahfam the symptoms are very much the same. One is contagious and one is not. No cure for Lupus. Systemic Lupus Erythematosis being the worst and developed by most sufferers
Sb you need harden up you little snowflake. Learn to tell the truth too. Not sure if l would use mong, minge more apt l think.
And if you look at the research update for it last July, Lupus looks remarkably like Covid19-
(From the RNS)- 'These studies were supported by a research grant from the US Department of Defense (DoD) and the report was recently published on the website of the Defense Technical Information Center (https://apps.dtic.mil/sti/citations/AD1087498).
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options. They also noted that the results could influence treatments of other autoimmune diseases such as arthritis and psoriasis.
Specifically, it was reported that treatment with TYK2/JAK1 inhibitor SAR-20351 (now known as SDC-1802) reduces autoantibodies (biological markers of lupus severity) in a spontaneous mouse model of SLE. The data also provided evidence that SAR-20351 inhibits cytokines that play a critical role in lupus, including interferon-alpha, IL-6 and IL-23. The inhibition of IL-23 signalling by SAR-20351 may play a role in the decrease of autoantibodies in the lupus mouse model, as IL-23 signalling drives the differentiation of Th17 cells, which leads to autoantibody production and are pathogenic in lupus'.
Still massively undervalued and in so many words Tyk2 is a blockbuster of epic proportions.
One thing is for certain we should have been at 8p back in Dec when we got the US patent grant and leading to worldwide patent protection for1802 which is very similar to 1801 and was studied by the US Army in Lupus. 1802 shows no tox and is almost ph1 ready with no competition in the tyk2 cancer area.
Thursdays are normally a good RNS day- although I doubt we'll get one. But with Sar you never know.
Hi Potnak. Reading yesterdays RNS based on the wording I anticipate news ref Covid studies early next month, "experimental phases finishing by the end of June". Not a bad thing as it would appear the price will gradually rise each day (or not so gradually!)
"The UKRI-funded Covid-19 research project for SDC-1801 continues on schedule with the experimental phases finishing by the end of June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available."
I don't know. I thought 10p on successful POC but I was wrong. I think we will spike the retrace. Where to, I don't know. We are attracting the dumb money now. The punters who buy with no research so who knows where it will land.
No speeding ticket with a 30% rise this morning tells us that 10p is still considered to be a good valuation.
I'm still half expecting a 3rd tranche of shares for the HNW hopefully with warrants at 10p. We might even get a TR1 and find out who it is. though I suspect they would rather stay anonymous. If no news tomorrow then next week and the more I think about the more I think that 1801 covid will be on licensed.
I think, news on the POC, news on the patent, news on a partner. All in quick succession.